A Phase 4 interventional study of Clopidogrel and Cilostazol in Type 2 Diabetes and Atherosclerosis, sponsored by Seoul National University Bundang Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Seoul National University Bundang Hospital · Phase 4, Interventional, and Prevention
Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's planned enrollment of 120 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Individuals with bleeding or conditions that may increase the risk of bleeding, such as:
Clopidogrel 75mg once daily
Drug: Clopidogrel
Cilostazol 200mg per day
Drug: Cilostazol
Clopidogrel 75mg once daily
Also known as: Platless Tab.
Cilostazol 200mg per day
Also known as: Cilostan CR Tab. 200mg
Changes of carotid intima-media thickness
mm
Time frame: 52 weeks
Changes of circulation
measured by ankle brachial index and laser doppler
Time frame: 52 weeks
Changes of HbA1c
%
Time frame: 26 and 52 weeks
Changes of glucose
mg/dL
Time frame: 26 and 52 weeks
Changes of body weight
kg
Time frame: 26 and 52 weeks
Changes of whole body fat
measured by bioelectrical impedance analysis
Time frame: 26 and 52 weeks
Changes of blood pressures
systolic, diastolic (mmHg)
Time frame: 26 and 52 weeks
Changes of lipids
total cholesterol, triglycerides, LDLc, HDLc (mg/dL)
Time frame: 26 and 52 weeks
Changes of peripheral pain or ischemic symptoms
measured by questionnaires (visual analogue scale: 100)
Time frame: 26 and 52 weeks
Changes of laboratory values related to blood clot
prothrombin time, activated partial thromboplastin time
Time frame: 26 and 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Bundang Hospital